Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers July 17, 2018
Pharmacy Choice - News - Over-the-Counter Drugs - July 17, 2018

Pharmacy News

 Over-the-Counter Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 26     Next >>     Go To Page:

7/16/18 - Concentric Analgesics Initiates Phase 2 Clinical Study of CA-008 for the Treatment of Post-Surgical Pain
Concentric Analgesics, Inc., a clinical-stage biopharmaceutical pain company, announced today that it has initiated a Phase 2 clinical study of CA-008, the Company s lead product candidate for the treatment of post-surgical pain. CA-008 is a water-soluble non-opioid prodrug that rapidly converts to capsaicin, a potent TRPV1-agonist which selecti
7/16/18 - OPKO Partner Vifor Fresenius Receives Marketing Approval for RAYALDEE in Canada
OPKO Health, Inc. announced today that the Company s partner Vifor Fresenius Medical Care Renal Pharma has received approval from Health Canada to market RAYALDEE in Canada for the treatment of secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease and vitamin D insufficiency.. OPKO Health launched RAYALDEE in the
7/16/18 - Patent Issued for Tamper-Resistant Pharmaceutical Dosage Forms and Process for Making Same (USPTO 10010620)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Alexandria, Virginia, by NewsRx journalists, a patent by the inventors Ghebre-Sellassie, Isaac; Terefe, Hibreniguss, filed on March 2, 2016, was published online on July 3, 2018. The assignee for this patent, patent number 10010620, is ExxPha
7/16/18 - Phase 3 CREDENCE Renal Outcomes Trial of INVOKANA (canagliflozin) is Being Stopped Early for Positive Efficacy Findings
The Janssen Pharmaceutical Companies of Johnson& Johnson today announced that the Phase 3 CREDENCE clinical trial, evaluating the efficacy and safety of INVOKANA versus placebo when used in addition to standard of care for patients with chronic kidney disease and type 2 diabetes, is being stopped early based on the achievement of pre-specified
7/16/18 - Systemic Lupus Erythematous SLE Drugs Market to Record an Exponential CAGR by 2025: Major drivers for global systemic erythematous drugs market are development of novel SLE therapies, increasing availability of bio similar drugs and increasing suppor
Valley Cottage, NY 07/16/2018 Systemic Lupus Erythematous is a chronic autoimmune disease which causes the immune system to mistakenly attack health body tissue. In SLE, body immune system can affect any part of the body, such as joints, organs, eyes, skin, etc. Often SLE can result in symptoms such as malar rash, discoid lesions, sub-acute c
7/16/18 - Vizuri Health Sciences LLC Announces the Appointment of Elise Donahue to its Board of Directors.
By a News Reporter-Staff News Editor at Clinical Trials Week Vizuri Health Sciences LLC, a pharmaceutical and over-the-counter product development company, announced that the company has further strengthened its consumer healthcare operational and transactional experience by adding Ms. Elise Donahue to its board of directors. Ms. Donahue, also se
7/16/18 - Vizuri Health Sciences LLC Granted New US Patent for Novel Topical Analgesic Formulations Containing Capsaicin
Vizuri Health Sciences LLC, a pharmaceutical and over-the-counter product development company, today announced the issuance of a U.S. patent that further protects its capsaicin-based product pipeline. Newly issued U.S. Patent 9,956,190, titled Topical Compositions for Pain Relief, Manufacture and Use, grants Vizuri exclusive rights to certain
7/14/18 - U.S. FDA Extends Review Timeline for INVOKANA(R) (Canagliflozin) Supplemental New Drug Application
Janssen Pharmaceutical Companies, a subsidiary of Johnson and Johnson, issued the following news release:. The Janssen Pharmaceutical Companies of Johnson& Johnson today announced that the U.S. Food and Drug Administration has extended the review timeline for a supplemental New Drug Application for INVOKANA (R). Janssen announced the sNDA submissio
7/13/18 - BioElectronics Files FDA Application for Treatment of Musculoskeletal Pain [Arab Finance (Egypt)]
-BioElectronics Corporation, www.bielcorp.com is pleased to announce that a Traditional 510 Premarket Notification for ActiPatch was filed today with the U.S. Food and Drug Administration. The 510 was prepared by the R&D team comprising: Kenneth McLeod, Ph.D., Director of Clinical Science and Engineering Research, State University of New York at Bi
7/13/18 - PFIZER TO ORGANIZE FOR FUTURE GROWTH
NEW YORK- Pfizer Inc. today announced it will organize the company into three businesses: a science-based Innovative Medicines business which will now include biosimilars and a new hospital business unit for anti-infectives and sterile injectables; an off-patent branded and generic Established Medicines business operating with substantial autonomy.
7/13/18 - U.S. FDA Extends Review Timeline for INVOKANA (canagliflozin) Supplemental New Drug Application
The Janssen Pharmaceutical Companies of Johnson& Johnson today announced that the U.S. Food and Drug Administration has extended the review timeline for a supplemental New Drug Application for INVOKANA . Janssen announced the sNDA submission in October 2017 and with this extension the action date is now in October 2018. INVOKANA was approved
7/12/18 - AbbVie Announces Submission of Supplemental New Drug Application to US FDA for Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy
AbbVie, a research-based global biopharmaceutical company, today announced it submitted a supplemental New Drug Application to the U.S. Food and Drug Administration for venetoclax in combination with a hypomethylating agent or in combination with low-dose cytarabine for the treatment of newly diagnosed patients with acute myeloid leukemia who are
7/12/18 - Active Pharmaceutical Ingredients Market Will Multiply at a CAGR of 6.4% During the Forecast Period of 2017 to 2023
Albany, NY 07/12/2018 Global Active Pharmaceutical ingredients Market: Overview. Active pharmaceutical ingredients are bulk drug products that are used as raw materials for formulations. APIs of good quality are essential for the manufacture of effective and safe medicines.
7/12/18 - Allergan Expands REFRESH Portfolio With New REFRESH REPAIR Lubricant Eye Drops
DUBLIN- Allergan plc, a leading global pharmaceutical company, today announced the launch of a new over-the-counter artificial tear formulation, REFRESH REPAIR Lubricant Eye Drops. The first and only artificial tear in the U.S. formulated with carboxymethylcellulose, hyaluronic acid, and osmoprotectants, REFRESH REPAIR is the latest addition to the
7/12/18 - BAUSCH + LOMB ANNOUNCES U.S. FDA FILING ACCEPTANCE FOR LOTEPREDNOL ETABONATE OPHTHALMIC GEL, 0.38%
BRIDGEWATER- Bausch+ Lomb, a leading global eye health company, today announced that the U.S. Food and Drug Administration has accepted the New Drug Application for its sub-micron loteprednol etabonate ophthalmic gel, 0.38% with a Prescription Drug User Fee Act action date of February 25, 2019. 'The sub-micron loteprednol etabonate ophthalmic gel,
7/12/18 - BioElectronics Files FDA Application for Treatment of Musculoskeletal Pain
BioElectronics Corporation, www.bielcorp.com is pleased to announce that a Traditional 510 Premarket Notification for ActiPatch was filed today with the U.S. Food and Drug Administration. The 510 was prepared by the R&D team comprising: Kenneth McLeod, Ph.D., Director of Clinical Science and Engineering Research, State University of New York a
7/12/18 - Genentech Announces Submission of Supplemental New Drug Application for Venclexta for People With Previously Untreated Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy
Genentech, a member of the Roche Group, today announced submission of a supplemental New Drug Application to the U.S. Food and Drug Administration for Venclexta , in combination with a hypomethylating agent or in combination with low dose cytarabine, for treatment of people with previously untreated acute myeloid leukemia who are ineligible for i
7/12/18 - HEALTH & SUPPORT
Monday evenings at 63 Jefferson Ave., Salem; and from noon to 1:30 p.m. Fridays at 75 Lindall St., Danvers. The Beverly and Addison Gilbert Hospital's Speakers Bureau is a free service designed to bring timely information on a variety of health-related topics. Held 7-8: 30 p.m. on the last Wednesday of each month in the doctors' conference room at
7/12/18 - Pfizer reverses some drug price hikes [Arab Finance (Egypt)]
Pfizer has reversed price increases on some drugs following White House pressure and the US drugmaker on Wednesday pledged to decide soon whether to sell its consumer drugs business. The move came a day after President Donald Trump threatened action on drug prices, saying on Twitter that Pfizer and others who lifted prices should be "ashamed."
7/12/18 - Pfizer to Organize for Future Growth
Pfizer, a pharmaceutical company, issued the following news release:. Pfizer Inc. today announced it will organize the company into three businesses: a science-based Innovative Medicines business which will now include biosimilars and a new hospital business unit for anti-infectives and sterile injectables; an off-patent branded and generic...
7/11/18 - Over-the-Counter (OTC) Drugs and Dietary Supplements Market 2018 Global Growth, Opportunities and Industry Analysis Forecast to 2023: Over-the-Counter (OTC) Drugs and Dietary Supplements -Market Demand, Growth, Opportunities and Analysis Of Top Key P
New York, NY 07/11/2018 Over-the-Counter Drugs and Dietary Supplements Industry. ALACER CORP. ALCON INC. ALFRESA PHARMA CORPORATION ALKALON A/S ALLERGAN, PLC. ALLIANCE HEALTHCARE ALTICOR ARKOPHARMA PHARMACEUTICAL LABORATORIES ASPEN HOLDINGS ASPEN PHARMACARE AUSTRALIA PTY. LTD. BAUSCH& LOMB BAYER HEALTHCARE AG BOEHRINGER INGELHEIM GMBH CARMA..
7/11/18 - Pfizer reorganizes to handle aging consumers and patents
Pfizer, facing an aging population and shifting risks from the loss of patents, is reshaping the company into three businesses. The three divisions, announced Wednesday, include Innovative Medicines, which will focus on biological science and other technologies needed to address an aging population. The Established Medicines business will handle ge
7/11/18 - Pfizer to Organize for Future Growth
Pfizer Inc. today announced it will organize the company into three businesses: a science-based Innovative Medicines business which will now include biosimilars and a new hospital business unit for anti-infectives and sterile injectables; an off-patent branded and generic Established Medicines business operating with substantial autonomy within...
7/10/18 - Allergan Expands REFRESH Portfolio With New REFRESH REPAIR Lubricant Eye Drops
Allergan plc, a leading global pharmaceutical company, today announced the launch of a new over-the-counter artificial tear formulation, REFRESH REPAIR Lubricant Eye Drops. The first and only artificial tear in the U.S. formulated with carboxymethylcellulose, hyaluronic acid, and osmoprotectants, REFRESH REPAIR is the latest addition to the
7/10/18 - Indonesia Pharmaceutical Market Outlook to 2022 - Analysis by Therapeutic Segment, Domestic & International Players, Generic & Patent Drugs, OTC & Prescription Drugs and Region
The "Indonesia Pharmaceutical Market Outlook to 2022- By Therapeutic Segment, By Domestic and International Players, By Generic and Patent Drugs, By OTC& Prescription Drugs, By Region" report has been added to ResearchAndMarkets.com' s offering. The report provides information on market size for Indonesia Healthcare and pharmaceutical.
Articles(s): 1 - 25 of 26     Next >>     Go To Page:


© 2018 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2018 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415